Understand the source comparison
Do Peptides Help With Wound Healing: Peptide Comparison by Mechanism
BPC-157 NO pathway stabilization, VEGF upregulation, angiogenesis promotion RCT: 38% faster healing in diabetic ulcers (Diabetes Care 2021) 250–500 mcg subcutaneous, daily for 4–8 weeks Subcutaneous injection near wound site Strongest evidence for vascular-dep
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- NO pathway stabilization, VEGF upregulation, angiogenesis promotion
- RCT: 38% faster healing in diabetic ulcers (Diabetes Care 2021)
- 250–500 mcg subcutaneous, daily for 4–8 weeks
- Subcutaneous injection near wound site
- Strongest evidence for vascular-dependent wounds; requires injection for deep tissue penetration
- Thymosin Beta-4 (Tβ4)
- Actin sequestration, keratinocyte migration, anti-inflammatory cytokine modulation
- Phase II: 72% ulcer size reduction vs 41% placebo (Wound Medicine 2019)
- 2–5 mg subcutaneous, twice weekly
- Subcutaneous injection or topical gel (limited penetration)
- Excellent for epithelialization; limited bioavailability via topical route
- GHK-Cu (Copper Peptide)
- MMP regulation, collagen remodeling, antioxidant activity via copper ions
- Clinical trial: 41% reduction in hypertrophic scarring (Wound Repair Regen 2017)
- 1–3% topical solution, applied twice daily
- Topical (penetrates stratum corneum due to low MW)
- Best for surface wounds and scar prevention; copper sensitivity must be assessed
- KPV (Lys-Pro-Val)
- α-MSH pathway modulation, anti-inflammatory signaling in enterocytes and skin
- Preclinical: reduced inflammatory cytokine expression by 60% in IBD models
- 500 mcg–1 mg subcutaneous or oral (limited absorption)
- Subcutaneous preferred; oral has <5% bioavailability
- Emerging evidence for inflammatory wounds; less studied than BPC-157 or Tβ4
- Thymalin
- Thymus-derived peptide complex, immune modulation, T-cell differentiation support
- Observational studies in post-surgical wound healing; limited RCT data
- 5–10 mg intramuscular, 5–10 day cycles
- Intramuscular injection
- Immune support role; indirect wound healing benefit via reduced infection risk